TrialCirculation2020

Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial.

Nicholas A Marston et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.